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Abstract
Background: Gestational diabetes mellitus (GDM) is one of the most common medical complications of
pregnancy, and has important health implications for mother and child. Changes in the fetoplacental vessels may
predict those in the vasculature of the developing fetus, as these have been implicated in the pathogenesis of
human GDM. This study aimed to determine the differences in the localization and expression level of VEGFA and
VEGFR2 between placentas of women with GDM and placentas of normal pregnancies, which is the first step in
elucidating the possible roles of VEGFA and VEGFR2 in the altered uteroplacental function resulting from maternal
hyperglycaemia and ultimately in the manifestation of GDM.
Methods: The expressions of VEGFA and VEGFR2 mRNA and protein in 20 samples from each group were
analyzed by real-time PCR, immunohistochemistry and Western blot. The placental blood barrier and
angiogenesis were observed by the transmission electron microscopy (TEM) in10 GDM samples and ten
controls.
Results: The expression levels of VEGFA and VEGFR2 mRNA and protein were significantly decreased in the
GDM group (P < 0.05 or 0.01). Immunohistochemical analysis showed the reduced expression of VEGFA and
VEGFR2 protein in GDM-affected placental tissues, and the degenerative alterations of the terminal villi
vascular.
Conclusion: The expressions of VEGFA and VEGFR-2 mRNAs and protein were reduced in GDM-affected
placental tissues, suggesting that maternal GDM affects the pathophysiological function of placentas.
Keywords: GDM, Placenta, Vascular endothelial growth factor, Receptors, Fetal development
Background
Gestational diabetes mellitus (GDM) is defined as any
degree of glucose intolerance with onset or first recogni-
tion during pregnancy, regardless of whether or not
diabetes persists after pregnancy [1–3]. Pregnancy is a
diabetogenic state characterized by impaired insulin
sensitivity, especially in the second trimester. The major
factors contributing to GDM are the placental hor-
mones, such as human placental lactogen, progesterone,
cortisol, growth hormone and prolactin. These hor-
mones cause the decreased phosphorylation of insulin
receptor substrate-1 (IRS-1), resulting in profound insu-
lin resistance [4–6]. As reported previously, IRS-1
decreases 50–60 % of insulin sensitivity and 50 % of beta
cell function in a normal pregnancy [7], and to maintain
euglycemia, the pancreas should compensate by increas-
ing insulin secretion by 2–2.5 times. However, beta cell
function deteriorates in GDM, particularly during the
first phase of insulin secretion.
Gestational diabetes mellitus (GDM) is one of the most
common medical complications of pregnancy, and has im-
portant health implications for mother and child. Mothers
with GDM have an excess of hypertensive disorders
during pregnancy, recurrence of gestational diabetes [8],
post-partum diabetes and cardiovascular disease thereafter
[9–11]. Pregnancies complicated by GDM are associated
with several adverse outcomes in the offspring including
* Correspondence: 1325825613@qq.com; cuiygnj@njmu.edu.cn
†Equal contributors
3Jiangsu Institute of Planned Parenthood Research, 277 Fenghuang Xijie,
Nanjing 210036, China
2The State Key Laboratory of Reproductive Medicine, Center of Clinical
Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University,
300 Guangzhou Road, Nanjing 210029, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Meng et al. Reproductive Biology and Endocrinology  (2016) 14:61 
DOI 10.1186/s12958-016-0191-8
macrosomia and a longer-term risk of the development of
obesity and type 2 diabetes [12].
Fetoplacental vessels are found in chorionic villi
bathed in maternal blood, and this close proximity per-
mits efficient exchange of solutes and gases between the
maternal and fetal circulations without intermingling of
the two. The arrangement allows the development,
growth, and remodeling of fetoplacental vessels to be
matched to the fetal need while rendering them vulner-
able to changes on both the maternal and fetal sides of
the placenta. Any pathological alterations in maternal
hemodynamics; maternal blood properties (such as hyp-
oxia or hyperglycemia); or growth factors such as vascu-
lar endothelial growth factors (VEGFs), soluble fms-like
tyrosine kinase-1 (sFlt1), soluble endoglin (sEng) and
inflammatory mediators may directly influence the
growth, maintenance, and function of fetoplacental ves-
sels. Furthermore, changes in the fetoplacental vessels
may predict those in the vasculature of the developing
fetus, as these have been implicated in the pathogenesis
of human GDM.
VEGF is a homodimeric disulfide-linked glycoprotein
involved in both angiogenesis (growth of new blood ves-
sels from existing ones) and vasculogenesis (de novo for-
mation of blood vessels) [13, 14]. VEGF family members
include VEGFA, (PlGF, VEGFB, VEGFC, and VEGFD)
and two members that are not expressed in mammals
(VEGFE, which is expressed in viruses, and VEGFF,
which is found in snake venom) [15, 16]. VEGFs initiate
cellular responses by interacting with tyrosine kinase re-
ceptors on the cell surface. Tyrosine kinase receptors are
a specific type of protein kinase receptor that functions
by phosphorylating the substrate to stimulate cellular re-
sponses. The VEGF receptor (VEGFR) consists of an
extracellular domain, a single transmembrane spanning re-
gion, and an intracellular component containing a tyrosine
kinase domain. There are three main VEGF-R subtypes:
VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1), and VEGFR3
(Flt-4). VEGFA binds to VEGFR1 and VEGFR2; VEGFB,
to VEGFR1; and VEGFC and VEGFD, to VEGFR2
and VEGFR3 [17]. The soluble form of VEGFR1
(sFlt1 or sVEGFR1) is a splice variant lacking the
transmembrane and cytoplasmic domains. Therefore,
it circulates and acts as a potent VEGF and PlGF an-
tagonist by preventing them from reacting with their
endogenous receptors [18, 19].
This study aimed to determine the differences in the
localization and expression level of VEGFA and VEGFR2
between placentas of women with GDM and placentas
of normal pregnancies, which is the first step in eluci-
dating the possible roles of VEGFA and VEGFR2 in the
altered uteroplacental function resulting from maternal




Women with a history of pregestational diabetes and
those with a non-singleton index pregnancy were ex-
cluded. A 75-g oral glucose tolerance test (OGTT) was
performed with plasma glucose measurement fasting
and at 1 and 2 h for women at 24–28 weeks of gestation
who were not previously diagnosed with overt diabetes.
The OGTT should be performed in the morning after an
overnight fast of at least 8 h. The diagnosis of GDM
is made when any of the following plasma glucose
values are exceeded, based on the American Diabetes
Association [20]: (1) fasting ≥ 5.1 mmol/l (92 mg/dl),
but <7.0 mmol(126 mg/dl); (2) 1 h ≥ 10.0 mmol/l
(180 mg/dl); (3) 2 h ≥ 8.5 mmol/l (153 mg/dl). After
GDM was diagnosed, those GDM women were asked diet
control to meet the satisfying range of fasting blood glu-
cose (3.3 to 5.6 mmol/L). These patients who were con-
sistently not following the strict management of GDM,
without medical therapy initiated. Fourteen patients from
this group (n = 20) were obese [BMI > 28, BMI = Body
weight (kg)/Body surface area2 (m2)] and four were hyper-
tensive. The clinical data on maternal age and weight,
number of gestational weeks, mode of delivery, BMI and
weight of placenta were summarized in Table 1. Twenty
women with normal pregnancies matched with GDM
women for number of gestational weeks, maternal age
and mode of delivery were recruited as the control group
(n = 20). Women in each group provided their placental
samples at delivery with the signed informed consent. The
study procedure was approved by the ethics committee of
the First Affiliated Hospital of Nanjing Medical University
(2013-SR-018, 2013) Additional file 1: Table S1.
Placental sample collection
In this study, all the subjects underwent delivery by
cesarean section due to various reasons such as anxiety
and tension, a burning desire of cesarean section and ex-
cessive afraid of pain,, other than those related to patho-
logical procedures, to avoid the potential affects of the
delivery procedure or other pathological factors on the
expression of VEGF system. The placental specimens
were weighed and performed on the basis of obstetric
indications. The tissue specimen was dissected from the
placental subchorial zone corresponding to the umbilical
cord insertion (approximately 5 cm away from the site
of cord insertion), while avoiding areas of infarction and
hematomas. Placentas with abnormal umbilical cord in-
sertions such as velamentous cord insertion were excluded
from the analysis. Tissue fragments from the placenta
were cut longitudinally from the maternal side to the fetal
side. Placental tissues were divided into three parts, mater-
nal, middle, and fetal, as described by Sood et al. [21]. The
middle part, consisting of homogeneous villous tissues,
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was collected and placed in ice-cold phosphate-buffered
saline (PBS), cleaned of blood, and immediately cut into
four 1 cm× 1 cm× 1 cm fragments, which were frozen
and stored at –80 °C for RNA analysis.
TEM examination
For the ultrastructural examination, ten women in each
group were randomly selected to provide their placental
samples at delivery (Additional file 1: Table S1). Until
delivery, eight GDM women (8/10) kept in the A1 class
(fasting glucose less than 5.8 mmol/L, postprandial
blood glucose less than 6.7 mmol/L) after good diet
control. Two GDM women (2/10) were classed as A2
(fasting blood glucose higher than or equal to 5.8 mmol/L,
postprandial blood glucose higher than or equal to
6.7 mmol/L) because of their poor diet control. The levels
of fasting blood glucose and HbA1c in those GDM
women with good diet control in the last weeks of
gestation were kept in the range of 5.1 to 5.6 mmol/L.
However, the level of fasting blood glucose (6.1 and
11.3 mmol/L) and the level of HbA1c (10.2 and
10.3 mmol/L) in two GDM women with poor diet control
were higher than the satisfactory criteria. Women with
normal pregnancies matched with GDM women for num-
ber of gestational weeks, maternal age and mode of deliv-
ery were recruited as control (Additional file 1: Table S1).
Three villous tissue blocks per placental sample were pre-
pared for the ultrastructural examination using TEM. The
samples were fixed in 2.5 % glutaraldehyde in cacodylate
buffer, and stored in cacodylate buffer with 0.05 M sac-
charose (pH 7.2) at 4 °C until processing. The villous tis-
sues were then post-fixed in 1 % OsO4 for 2 h at 4 °C,
routinely processed in a graded series of acetone, then
infiltrated with acetone-araldite and embedded in araldite.
For orientation, semithin sections (thickness, 1 μm) were
stained with thionine. Ultrathin sections (thickness, 80 nm)
were treated (double contrast) with uranyl acetate (25 min)
and 8 % lead nitrate (5 min) and then systematically exam-
ined in a JEM-1010 electron microscope (JEOL Ltd).
Terminal villi were evaluated with respect to the pla-
cental blood barrier (thickness of the vasculo-syncytial
membrane, thickness of the syncytiotrophoblast (ST)
basal membrane (BM), and thickness of the endothelial
BM). For each tissue block, five microscopic fields were
randomly selected and systematically investigated at
5000×, 12,000×, and 25,000× magnification for quantita-
tive analysis. Thus, a total of 15 random fields were re-
corded and analyzed per placenta to minimize individual
differences. The following three measurements were per-
formed for each field: thickness of the vasculo-syncytial
membrane from the intervillous space to the fetal ves-
sels, perpendicular to the BM, at 5000× magnification;
microvillous density per 10 μm of length at 12 000×
magnification; and thickness of the ST or endothelial
BM was measured at 25,000× magnification. Images
were analyzed using the TEM Image Platform (Olympus)
to perform random measurements. The two operators
who carried out the microscopic analyses were blinded
to the placental group until the end of the study.
Immunohistochemistry
Twenty tissue blocks in each group were sectioned
and fixed to slides with the placenta and stained to-
gether. VEGF-A immunostaining: Slides were de-
waxed, rehydrated, antigen retrieved and bathed in
hydrogen peroxide for 30 mins. Blocking was done with
Normal Donkey Serum (NDS). Rabbit anti-VEGFA anti-
body (VEGF (ab105219) (1:50) (500 μg/ml) (Abcam) and
DAR-555 (1:1000) were used as primary and secondary
antibody respectively.
VEGFR2 Immunostaining: Slides were de-waxed, rehy-
drated, antigen retrieved and bathed in hydrogen peroxide
for 30 mins. NDS was employed to block non-specific
antibody binding. Rabbit anti-VEGFR2 antibody (55B11)
(1:200) (100 μg/ml) (Cell Signaling) and DAR-555 (1:1000)
were used as primary and secondary antibody respectively.
RNA extraction and cDNA preparation
Total RNA was extracted from twenty placenta tissues
from each group using Trizol Reagent (Invitrogen,
Carlsbad, CA). RNA was treated with DNase using
TURBO DNA-free kit (Ambion, Austin, TX), and purified
with an RNeasy mini kit (Qiagen Inc., Valencia, CA). Spec-
trophotometric analysis and gel electrophoresis were used
to determine the yield, purity, and integrity, and to ensure
the lack of genomic DNA contamination in the samples.
cDNA was prepared from total RNA using a high-capacity
cDNA reverse transcriptase kit (Applied Biosystems,
Foster City, CA).
Table 1 Clinical characteristics of GDM women and the control







Gestation, weeks 39.41 ± 0.96 39.00 ± 0.90 0.34a
Maternal age, years 28.4 ± 5.5 31.4 ± 6.7 0.13a
Maternal BMI, kg/m2 24.27 ± 2.18 28.23 ± 2.94 0.02a*
Mode of delivery Cesarean Cesarean -
Sex of newborn 0.53b
Male 9(45) 12(60)
Female 11(55) 8(40)
Birth weight of newborn, g 3621 ± 380 3744 ± 537 0.29a
Placental weights, g 734 ± 31.5 752 ± 33.2 0.11a
BMI body weight (kg)/body surface area2 (m2). aStudent’s t test.; bx2 test. *P < 0.05
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First-strand synthesis was performed on 2 μg of total
RNA using Superscript II/III ribonuclease H-reverse
transcriptase (Invitrogen, Australia).
Real-time PCR
The mRNA expression of VEGF-A and VEGFR-2 in the
placental samples obtained from the GDM and control
pregnancies were quantified in an ABI Prism 7700
(Perkin-Elmer/Applied Biosystems) using prevalidated
Assays on Demand (consisting of a 20× mix of unlabeled
HLX1-PCR primers and FAM-dye labeled TaqMan MGB
probe; HLX1 Assays on Demand, catalog no. 4331182;
Applied Biosystems). Gene expression was quantified as
the second step in a two-step RT-PCR protocol ac-
cording to the manufacturer’s instructions. In brief, the
20-μL PCR reaction mix contained TaqMan Universal
PCR master mix, 1× Assays on Demand gene expression
assay mix, and 1 μL of placental cDNA. The sample was
amplified for 40 cycles, including a denaturation step at
95 °C for 15 s and an annealing/extension step at 60 °C
for 30 s. The oligonucleotide primers used for the ampli-
fication of the gene VEGF-A and VEGFR-2 were as
follows: VEGF-A forward primer, 5′-TGCGGATCA
AACCTCACCAA-3′ and VEGF-A reverse primer, 5′-
TGTCACATACGC TCCAGGACTT-3′; VEGFR-2 for-
ward primer, 5′-GTGTCAGAATCCCTGCGAAGTA-3′
and VEGFR-2 reverse primer, 5′-GAAATGGGATTGG
TAAGGATGA-3′. Actin was used as a housekeeping
gene. The primers were designed using Primer Express
1.5 software (Applied Biosystems). A mixed sample was
used as the sample of quality control (QC). In every
assay, the QC sample was added to two wells in the
same 96-well plate. The average Ct of actin was calcu-
lated and normalized to test the variation within a assay.
The relative value of target gene in the QC sample was
2(Ct2-Ct1), which was used to correct the variation be-
tween assays. The relative quantitation of VEGF-A and
VEGFR-2 expression normalized to actin was calculated
according to the 2–ΔΔT method of Livak and Schmittgen
[22] using a term control as a calibrator (ABI Prism 7700
sequence detection system, User Bulletin no. 2, 2001).
Western immunoblotting
Twenty samples from each group were tested as follow-
ing protocol. Total protein was extracted from 20 mg of
snap-frozen placental tissue in 200 μL of RIPA lysis
buffer containing 50 mmol/L of Tris-HCl (pH 7.4), 1 %
Triton X-100, 1 % sodium deoxycholate, 150 mmol/L
NaCl, 0.1 % sodium dodecyl sulfate (SDS), sodium
orthovanadate, sodium fluoride, ethylenediaminetetra-
acetic acid (EDTA), and leupeptin using an Ultra-Turrax
(Ika-Labortechnik). The homogenized samples were
centrifuged at 10,000 g for 5 min at 4 °C to sediment any
insoluble material. The protein concentration of the
supernatant was determined using an Enhanced BCA
protein assay kit (Beyotime, China) with bovine serum
albumin (Sigma Aldrich, Australia) as the standard. Ap-
proximately 25 μg of protein per lane was fractionated
using 10 % SDS-polyacrylamide gel electrophoresis
(PAGE). The proteins were electrophoretically trans-
ferred to nitrocellulose membranes and blocked with
5 % nonfat milk in Tris-buffered saline (pH 7.4). Purified
rabbit polyclonal VEGFA (1/200; ab105219; VEGFA-121,
165, and 189; Abcam) and rabbit monoclonal
VEGFR2 (1/1000; 55B11; Cell Signaling) were used as
the primary antibodies. Antibody binding was visualized
using peroxidase-conjugated rabbit anti-mouse (Zymed,
Mulgrave, Australia) secondary antibody, and analyzed by
autoradiography using Fluorchem™ 5500 (Amersham
Biotech, Shanghai, China).
The total protein in each well was detected by
Coomassie blue staining to ensure constant protein load.
A mixed sample as the QC sample was added to two
wells in every plate from different assay. Tublin was used
as a housekeeping protein. The densitometry of tublin
was determined, and then the relative value of target
protein in the QC sample was normalized. The variation
within a assay was evaluated by two relative values, while
the variation between assays was also corrected by the
mean relative value. The expressions of VEGFA and
VEGFR2 protein were semiquantitatively determined
using Scanning Densitometry (Image Quant, Australia).
Statistical analysis
Data were expressed as the mean and standard deviation
(SD). Statistical analyses were performed using SPSS soft-
ware (Statistical Analysis System, version 17.0 for
Windows). Statistical differences between the two groups
were analyzed using Student’s t test for those data in
the normal distribution. Statistical significance was set
at p < 0.05.
Results
Summary of the clinical features
As shown in Table 1, the GDM group (n = 20) had a sig-
nificantly higher mean BMI than the control group
(28.23 ± 2.94 kg/m2 versus 24.27 ± 2.18 kg/m2, P = 0.02).
Other parameters such as gestation, maternal age, mode
of delivery, sex and birth weight of the newborn, and
placental weight did not significantly differ between the
groups.
TEM analysis
The placenta barrier was composed of ST, endothelium
and the space between them. ST was a continuous syn-
cytial layer with multiple nucleus and numerous apical
microvilli, while CT had a single large nucleu and scat-
tered distributed beneath the syncytium so that could
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not be seen in all the visual fields, which is analo-
gous in both groups. BM of ST was a continuous,
uniform, and thin basal lamina where collagen fibrils
occasionally deposited, which was same to the BM
of fetal endothelium. The stroma was the connective
tissue core of the chorionic villous space separating
ST from the capillary endothelium BM, and con-
tained different kinds of stromal cells and bundles of
collagen fibrils.
The placental blood barrier and angiogenesis were spe-
cially observed by TEM analysis. The vasculo-syncytial
membrane (VSM) and BM of ST were significantly higher
(P < 0.05) in the GDM group (6746.15 ± 1270.22 nm and
1077.49 ± 194.39 nm, respectively; Fig. 1a and d; n = 10)
than those in the control group (4591.34 ± 1178.60 nm
and 707.54 ± 256.56 nm, respectively; Fig. 1b and e;
n = 10). The density of ST apical microvilli per unit
surface area in the GDM group (44.36 ± 21.95 per
10 μm) was significantly lower than that in the con-
trol group (77.13 ± 20.82 per 10 μm; P < 0.05), as
shown in Fig. 1g–i.
Localization and distribution of VEGFA and VEGFR2
IHC was used to investigate the cellular distribution of
VEGFA and VEGFR2 proteins in GDM-affected (n = 20)
and control (n = 20) placental tissues. Figure 2a and c
showed the representative images of VEGFA immunore-
activity in the ST layer of term control tissues (Fig. 2a)
and term GDM tissues (Fig. 2c). Qualitative assessment
of the immunoreactivity revealed that the VEGFA pro-
tein level was lower in the placentas of the GDM group
than in those of the control group but with no discern-
able difference in protein localization. Figure 2b and d
showed the localization and distribution of the
VEGFR2 protein in the placental tissues. Qualitative
analysis revealed weaker staining in the endothelial
Fig. 1 Comparison of semiquantitative parameters of placental ultrastructures between the GDM group (n = 20) and the control group (n = 20).
a-b. The terminal villi of GDM (a) and control (b) placenta. c Placental barrier thickness (arrow) of the GDM group (6746.15 ± 1270.22 nm, n =10)
was significantly thicker than that of the control group (4591.34 ± 1178.60 nm, n = 10; P < 0.05), Bar = 5um. d-e The terminal villi of GDM (d) and
control (e) placenta. f. The BM of ST in the GDM group (1077.49 ± 194.39 nm nm, n= 10) was thicker than that in the control group (707.54 ± 256.56 nm,
n= 10; P< 0.05), Bar = 1um. g-h The density of ST apical microvilli in GDM (g) and control (h) placenta. i The density of ST apical microvilli in the GDM
group (44.36 ± 21.95 per 10um, n= 10) was significantly lower than that in the control group (77.13 ± 20.82 per 10um, n =10; P< 0.05), and even
microvilli-free in some areas, Bar =2um
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cells of fetal vessels in the placentas of the GDM
group (Fig. 2d) than that in the control group
(Fig. 2b), but no discernable difference in the
localization of VEGFR2 was noted.
VEGFA and VEGFR2 mRNA expression
Figure 3 illustrated the expressions of VEGFA and
VEGFR2 mRNAs. Relative to the level of the Actin
housekeeping gene, the VEGFA mRNA level was sig-
nificantly decreased in the GDM group (n = 20) when
compared with the control group (n = 20) (1.23 ± 0.53
versus 4.19 ± 2.61, P < 0.05; Fig. 3a). Similarly, the
relative expression of VEGFR2 mRNA was signifi-
cantly reduced in the GDM group when compared
with control group (1.66 ± 0.33 versus 3.64 ± 0.95, P <
0.01; Fig. 3b).
Protein expression of VEGFA and VEGFR2
Figure 3 also showed the representative immunoblots of
VEGFA and VEGFR2 proteins in the GDM-affected
(n = 20) and control placentas (n = 20). Representative
immunoblots of the 51-kDa housekeeping protein β-
tubulin was used to illustrate the protein load of all sam-
ples. The 27-kDa immunoreactive VEGFA protein was ob-
served in both groups. Semi-quantitative densitometry
showed the decreased expression of VEGFA protein in the
GDM group when compared with the control group (0.51
± 0.21 versus 1.31 ± 0.40, P < 0.05; Fig. 3c). Figure 3d
showed a 210-kDa protein of VEGFR2 in the GDM and
control samples. Densitometry also showed the decreased
VEGFR2 protein expression in the GDM group when
compared with the control group (0.59 ± 0.49 versus
1.60 ± 1.47, P < 0.05).
Discussion
The primary origin of fetal derangements in gestational
diabetic mothers is fetal hyperglycaemia resulting from
maternal hyperglycaemia. This hyperglycaemia may re-
sult in the metabolic and hormonal change in the fetus.
Once the fetal pancreas commences to produce and
secrete insulin in the second trimester [23], fetal hy-
perglycaemia will result in fetal hyperinsulinemia and
Fig. 2 Immunohistochemical staining to study the cellular localization of VEGFA and VEGFR2 proteins in the GDM and control placentas. Representative
controls (a, c and e) and GDM placentas (b, d and f) were stained with rabbit monoclonal antibodies to VEGFA (a and b) and VEGFR2(c and d). e and f
Omission of the primary antibody as control. Syncytiotrophoblasts (red arrows) and fetal vessels (green arrows). Scale bars: 20 μm
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stimulation of fetal metabolism. Lower fetal oxygen
content associated by higher lactate concentrations may
certainly reflect enhanced fetal metabolism as a result of
hyperglycaemia and hyperinsulinemia [24]. Consequently,
the improvement of fetal oxygen demands will aggravate
the chronic fetal hypoxia [25]. The hyperglycemia of
GDM develops during pregnancy and clinically manifests
only in the late second trimester and thus may have an
impact on placental processes occurring in later stages of
pregnancy, such as angiogenesis and microvascular re-
modeling. VEGF/VEGFR-2, which was selected as repre-
sentative factors related to the placental blood barrier and
angiogenesis in this study, is important in promoting vas-
cular endothelial cell growth and in increasing the number
of vessels and capillaries [22], thereby ensuring the ad-
equate supply of nutrients to the fetus, through classical
feedback mechanism. We found that the expressions of
VEGFA and VEGFR2 was significantly lower in the pla-
centas of women with GDM although we did not show
the relationship between above expressions and the in-
creased glucose levels or abnormal levels in their OGTTs
due to the limited sample size. There is consistent evi-
dence that the concentration of VEGF in GDM maternal
and cord plasma was decreased [26]. VEGF mRNA ex-
pression and protein production are oxygen-dependent,
which are known to be up-regulated by hypoxia [27]. Just
because of the strong proangiogenic potency of hypoxia
through regulating multiple steps of vascular growth [28],
chronic fetal hypoxia as the consequence of maternal dia-
betes may thus stimulate placental vasculogenesis and
angiogenesis by increasing the growth factors expression
in the placenta and fetus. Parallel to its regulation by oxy-
gen, placental VEGF is at a high level in the first trimester
when oxygen levels are low and decline thereafter towards
term of gestation [29–31], moreover the extent of hyper-
glycemia other than hypoxia may also contribute and
modify its effect [32]. Thus, the condition of hypergly-
cemia induces a state of mild and persistent ischemia and
Fig. 3 Expressions of VEGFA and VEGFR2 mRNAs and proteins in GDM (n = 20) and control (n = 20) placental tissues by real-time PCR and Western
immunoblotting. Relative quantification of VEGFA (a) and VEGFR2 (b) mRNA expression normalized to the expression of ACTIN in all the samples.
Data were analyzed according to the 2–ΔΔCT method. A representative immunoblots for VEGFA (c) and VEGFR2 (d) were shown. Immumoblots
representing β-tubulin protein (middle panels) showed the loading equally total protein (25 μg). Semi-quantitative analyses of VEGFA and VEGFR2
immunoreactive proteins were performed relative to β-tubulin (bottom panels). The Y-axis represents the expression levels of VEGFA and VEGFR2
related to actin or tubulin. *P < 0.05, **P < 0.01, Student’s t test
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hypoxia with subsequent increase of hypercapillarization.
In contrast, high blood glucose levels especially poorly
controlled in GDM trigger severe hypoxia/ischemia, with
inhibition of binding VEGF/VEGFR-2 and consequent re-
duction of hypercapillarization, and therefore fetal hypoxia
as a result of maternal diabetes does not stimulate the ex-
pression of VEGF in the third trimester [33]. The complex
process of villous development and maturity might be also
influenced by the maternal and fetal oxidative and other
angiogenetic milieu, which will result in endothelial dys-
function and oxidative stress [34]. As the placenta is one
of major sources of VEGF during pregnancy, our findings
suggested that the reduced expression of VEGF in pla-
centa in the GDM group may contribute to the patho-
genic vascular defects which could be observed on the
histological examination. Two other studies have also re-
ported that the placental expression and fetal cord levels
in GDM are significantly lower than normal [3235].
These data were confirmed by immunolocalization of
VEGF and VEGFR-2. The distribution of VEGF was ob-
served in the placentas of women with GDM, and no
VEGF was detected in the placental cellular compart-
ments, which suggested a decrease in VEGF production.
VEGF was always detected in the in the ST layer of term
control tissues and term GDM tissues [32], in women
with gestational diabetes there was a significant decrease
in VEGF expression profile when compared to normo-
glycemic women. The target cells for VEGF in the
chorionic villi were determined based on the immunolo-
calization of VEGFR-2, which expression was par-
ticularly low in the placental capillary endothelial cells of
gestational diabetes, in contrast to normoglycemic women.
The binding between VEGF and VEGFR-2 triggers a sig-
naling pathway that negatively regulates angiogenesis.
Our finding showed that distinct alternations of
ultrastructure in GDM placenta comparing with control
placenta. The significant differences in ultrastructure
may be summarized as the thickening of the vasculo-
syncytial membrane (VSM) and BM of ST, a decreased
number of ST apical microvilli per unit surface area in
the GDM group. These changes related to the reduced
VEGFA and VEGFR2 expressions may have adversely
affected the transport efficiency of the placental vas-
culature by the decreased transport of oxygen, nutrients,
and waste across the placenta [36]. To explore the com-
parable and inchoate changes in the VEGFA and
VEGFR2 expression and placental ultrastructure, we
excluded those cases with adverse pregnancy out-
comes or pathological placental tissuess in this study.
Our results suggested that this effect may be a re-
sponse to the placental hypoxia induced by hyper-
glycemia, which might have potential affect on the
placental and fetal development and growth during
pregnancy.
Conclusion
This observational study revealed the reduced expres-
sions of VEGFA and VEGFR2 in the placental tissues
obtained from women with GDM. It should be noticed
for both clinicians and GDM women that the reduced
VEGF/ VEGFR2 may affect the placental blood barrier
and angiogenesis, and consequent placental function, in
the pregnancy with GDM.
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